Go Back to Previous Page »

Prograf Antitrust Litigation -- Plumbers and Pipefitters Local 572 v. Astellas Pharma US, Inc.

Court: United States District Court, District of Massachusetts
Case No.: 1:11-cv-11870
Leadership Position: Plaintiffs’ Executive Committee

Wexler Wallace, together with co-counsel Branstetter Stranch & Jennings PLLC, filed a class action lawsuit against Astellas Pharma US, Inc. seeking damages and equitable relief under federal antitrust law and state antitrust and consumer fraud statutes for consumers and third-party payors (“Indirect Purchasers”) who have been forced to pay higher prices for Prograf, and its generic equivalents, due to Astellas’ anticompetitive conduct.

Defendant is the manufacturer of Prograf, a drug with immunosuppressive properties that is commonly used to prevent organ rejection in patients who have received heart, kidney, or liver transplants.  The complaint alleges that Defendant filed a baseless Citizen Petition with the FDA in order to delay generic competition in the market for Prograf.

To learn more about the case and view the Complaint, click here.